APPLIED PHARMACEUTICAL TOXICOLOGY 2020 - meeting cancelled

After careful consideration of the ongoing spread of COVID-19 (coronavirus) The Boston Society Board of Directors decided not to conduct APT 2020 Annual Meeting @ Takeda, Cambridge this month (May 12-14, 2020).

Save the Date for 2021!

May 11 - 13, 2021
Genentech, South San Francisco, CA

Plenary Speakers for 2020

		Jeffrey Gotts, MD, PhD Assistant Professor, Department of Medicine, UCSF Chasing the Cloud or Choking on it: The Pulmonary Toxicity of E-Cigarettes

		Daniel Nomura, PhD Professor of Chemical Biology, University of California at Berkeley Reimagining Druggability using Chemoproteomic Platforms

		Lisa Plitnick, PhD Senior Research Scientist, Merck Discovery and Development of Vaccines and Worldwide Regulatory Experience

Speakers Confirmed for 2020

		Christopher Aluise, PhD Senior Research Scientist, Toxicology, Eli Lilly and Company Title TBA		Rogley Boyce, DVM, PhD, DAVCP Consultant - Nonclinical Lead for Evenity, Amgen Nonclinical Cardiovascular Safety Evaluation of Romosozumab-aqqg

		Christopher Brynczka, PhD, DABT Senior Principal Scientist, Merck Title TBA		Paola Costaldi, PhD Associate Director, Head of Chemical Biology, AstraZeneca Title TBA

		Brian Enright, PhD, DABT Senior Principal Scientist, Preclinical Safety, AbbVie Utility of Juvenile Animal Studies for Antibody-Drug Conjugates		Juliane Gust, MD, PhD Center for Integrative Brain Research, Seattle Children's Hospital CAR T Neurotoxicity: Translational Insights

		Tracy Henriques, PhD, DABT Toxicologist, AbbVie Preclinical to Clinical Translation of ADA: Putting Data to the Dogma		Cris Kamperschroer, PhD Senior Principal Scientist, Pfizer Nonclinical Evaluation of CD3 Bispecific Molecules

		Lucas Kempf, MD Medical Officer, Rare Diseases Program, FDA Regulatory Challenges of Rare disease Drug Development		Hervé Lebrec, PharmD, PhD, DABT Scientific Director, Translational Safety & Bioanalytical Services, Amgen Experience with Nonhuman Primate Models in CAR-T Therapy Nonclinical Safety Assessment

		Lisa Mangus, DVM, PhD, DACVP Assistant Professor, Dept. of Molecular & Comparative Pathobiology, Johns Hopkins School of Medicine Intra-Epidermal Nerve Fiber Analysis: a Sensitive, Clinically-Relevant Tool for Assessing Sensory Nerve Damage in Animal Models		Kim Maratea, DVM, PhD, DACVP Associate Director Pathology, Oncology Safety, AstraZeneca Early Assessment of Bone Marrow Toxicity in Immunodeficient Mice

		John McNulty, PhD Director, Shire/Takeda Nonclinical Safety Considerations in the Development of Treatments for Rare Diseases at Shire		Scott Mittelstadt, PhD Director of Investigative Toxicology and Safety Pharmacology, AbbVie CiPA: Practical Applications in Discovery

		Suman Mukherjee, PhD Director, In Vivo PK and TK Group, Safety Assessment, Merck The Impact of Toxicokinetics on the Design and Interpretation of Toxicology Studies		Kara Pearson, PhD Director, Analytical and Biochemical Toxicology, Merck Using Stable Isotope Labeled Tracers to Illuminate Aspects of Hepatic Function and Provide a Translational Biomarker of BSEP Inhibition

		Michael Polydefkis, MD MHS Professor, Neurology, Johns Hopkins University School of Medicine TBA		Mohan Rao, PhD Computational Toxicologist/Biologist, AbbVie Tntegrating Cheminformatics and Off-Target Safety Assessments to Predict Testicular Toxicity

		Chandra Saravanan, PhD Senior Veterinary Pathologist, Novartis Institutes for BioMedical Research Title TBA		Nicola Stagg, PhD, DABT Senior Scientist/Toxicologist, Genentech Title TBA

		Jonathan Stauber, PhD Director, ImaBiotech Role of Drug Exposure Quantification for Safety and Efficacy Evaluation in Non Clinical and Clinical Trials		Jessica Sutherland, PhD, DABT Senior Director, Toxicology, Alnylam Pharmaceuticals The Nonclinical Safety Profile of ONPATTRO® (patisiran), a First-in Class RNAi Therapeutic for the Treatment of Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis)

		Larry Whiteley, DVM Senior Director, Pfizer Title TBA		Francis Wolenski, PhD, DABT Senior Toxicologist, Drug Safety Research & Evaluation, Takeda Navigating a Tough Regulatory Interaction – Is this Phase 1 or 2?